35791
document
Symptomatic treatment versus combination chemotherapy for patients with extensive non-small cell lung cancer . In a randomized clinical trial , 87 patients with inoperable , extensive non-small cell lung cancer ( NSCLC ) were randomized to receive either combination chemotherapy ( cisplatin at 70 mg/m2 intravenously [ i.v . ] on day 1 and etoposide at 100 mg/m2 i.v . on day 1 and 200 mg/m2 orally on days 2 and 3 ) or symptomatic treatment . No statistically significant differences in survival time were found between the two treatment techniques . A major problem in the interpretation of the results was the use of semicurative radiation therapy ( 3000 to 4200 cGy ) to the primary tumor and mediastinum , which was given with symptomatic intent . Three long-term survivors were seen in the latter group .
35792
Intervention_Physical
Symptomatic treatment
35793
Intervention_Pharmacological
combination chemotherapy
35794
Intervention_Pharmacological
combination chemotherapy ( cisplatin
35795
Intervention_Pharmacological
etoposide
35796
Intervention_Physical
symptomatic treatment
35797
Outcome_Mortality
survival time
35798
Outcome_Mortality
Three long-term survivors
35799
Participant_Condition
patients with extensive non-small cell lung cancer .
35800
Participant_Sample-size
87
35801
Participant_Condition
patients with inoperable , extensive non-small cell lung cancer ( NSCLC )